ObjectiveTo evaluate the immediate effectiveness and safety of four intranasal acupuncture methods based on different intranasal localizations of Neiyingxiang （EX-HN 9） for improving nasal ventilation in patients with allergic rhinitis （AR）. MethodsA total of 120 patients with AR were randomly divided into four groups with 30 cases in each group， the agger nasi group， the inferior turbinate-alar junction group， the inferior turbinate top group， and the nasal septum group. All patients received one 20-minute session of intranasal acupuncture. The agger nasi group received acupuncture at the agger nasi site， the inferior turbinate-alar junction group at the junction of the inferior turbinate and alar cartilage， the inferior turbinate top group at the top of the inferior turbinate directly facing the nostril， and the nasal septum group at Little's area of the nasal septum. Before acupuncture and within 5 min after treatment， the assessments and measurements were performed including nasal obstruction symptom evaluation （NOSE） scale used to evaluate the severity of nasal obstruction before and after acupuncture， a nasal resistance/nasal flow analyzer applied to detect nasal airway resistance （NAR） and nasal respiration volume （NS）， the visual analogue scale （VAS） adopted to assess pain intensity. The incidence of nasal bleeding and other adverse events were recorded， and patients' willingness to receive repeat treatment was statistically analyzed. ResultsCompared with baseline within group， all four groups showed decreased NOSE scores and NAR as well as elevated NS after treatment （all P＜0.05）. Compared with the agger nasi group and the inferior turbinate-alar junction group， the inferior turbinate top group had higher NOSE scores and lower NS； the nasal septum group presented higher NOSE scores and NAR alongside lower NS （P＜0.05）. The nasal septum group yielded significantly higher VAS scores than the other three groups （P＜0.05）， with 11 cases （36.67%） of massive nasal bleeding observed， while no severe nasal hemorrhage occurred in the remaining groups. The proportions of patients willing to receive repeated intranasal acupuncture treatment were 70.00% （21/30） in the agger nasi group， 76.67% （23/30） in the inferior turbinate-alar junction group， 43.33% （13/30） in the inferior turbinate top group， and 3.33% （1/30） in the nasal septum group， respectively， with statistical significant difference among groups （χ² = 39.91， P＜0.001）. ConclusionAll four intranasal acupuncture methods can immediately improve nasal ventilation in patients with AR. The agger nasi group and inferior turbinate-alar cartilage junction group achieved superior therapeutic improvement compared with the inferior turbinate top group and nasal septum group， accompanied by better safety and higher patient acceptability.

ObjectiveTo evaluate the immediate effectiveness and safety of four intranasal acupuncture methods based on different intranasal localizations of Neiyingxiang （EX-HN 9） for improving nasal ventilation in patients with allergic rhinitis （AR）. MethodsA total of 120 patients with AR were randomly divided into four groups with 30 cases in each group， the agger nasi group， the inferior turbinate-alar junction group， the inferior turbinate top group， and the nasal septum group. All patients received one 20-minute session of intranasal acupuncture. The agger nasi group received acupuncture at the agger nasi site， the inferior turbinate-alar junction group at the junction of the inferior turbinate and alar cartilage， the inferior turbinate top group at the top of the inferior turbinate directly facing the nostril， and the nasal septum group at Little's area of the nasal septum. Before acupuncture and within 5 min after treatment， the assessments and measurements were performed including nasal obstruction symptom evaluation （NOSE） scale used to evaluate the severity of nasal obstruction before and after acupuncture， a nasal resistance/nasal flow analyzer applied to detect nasal airway resistance （NAR） and nasal respiration volume （NS）， the visual analogue scale （VAS） adopted to assess pain intensity. The incidence of nasal bleeding and other adverse events were recorded， and patients' willingness to receive repeat treatment was statistically analyzed. ResultsCompared with baseline within group， all four groups showed decreased NOSE scores and NAR as well as elevated NS after treatment （all P＜0.05）. Compared with the agger nasi group and the inferior turbinate-alar junction group， the inferior turbinate top group had higher NOSE scores and lower NS； the nasal septum group presented higher NOSE scores and NAR alongside lower NS （P＜0.05）. The nasal septum group yielded significantly higher VAS scores than the other three groups （P＜0.05）， with 11 cases （36.67%） of massive nasal bleeding observed， while no severe nasal hemorrhage occurred in the remaining groups. The proportions of patients willing to receive repeated intranasal acupuncture treatment were 70.00% （21/30） in the agger nasi group， 76.67% （23/30） in the inferior turbinate-alar junction group， 43.33% （13/30） in the inferior turbinate top group， and 3.33% （1/30） in the nasal septum group， respectively， with statistical significant difference among groups （χ² = 39.91， P＜0.001）. ConclusionAll four intranasal acupuncture methods can immediately improve nasal ventilation in patients with AR. The agger nasi group and inferior turbinate-alar cartilage junction group achieved superior therapeutic improvement compared with the inferior turbinate top group and nasal septum group， accompanied by better safety and higher patient acceptability.

Lung cancer constitutes the most prevalent and lethal malignant tumor in China. Approximately 85% of lung cancer diagnoses correspond to the non-small cell histological subtype [non-small cell lung cancer (NSCLC)]. Despite surgery being the mainstay for early-stage disease, postoperative recurrence remains high and adjuvant chemotherapy offers limited benefit. In recent years, targeted therapy has demonstrated substantial advantages in driver mutation-positive NSCLC. To this end, the Lung Cancer Medical Education Committee of the Chinese Medical Education Association developed guidelines based on a systematic review of evidence through November 2025, using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach and a modified Delphi method. Focusing on epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and addressing ROS proto-oncogene 1 (ROS1), B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutation, and mesenchymal-epithelial transition factor (MET) exon 14 (METex14) skipping, the guideline covers molecular testing, neoadjuvant/adjuvant therapy, perioperative strategies, minimal residual disease monitoring, and postoperative surveillance. It defines testing requirements, specifies stage-directed and subtype-specific treatments, and standardizes minimal residual disease monitoring. These recommendations emphasize precision and feasibility to improve survival and quality of life.

Sepsis exhibits substantial biological heterogeneity. Transcriptome-based subtyping systems， such as sepsis response signature （SRS） subtypes， molecular diagnosis and risk stratification of sepsis （MARS）， inflammation/adaptive/coagulation subtyping， and consensus transcriptomic subtypes， have provided a crucial basis for elucidating the molecular mechanisms of sepsis and guiding precision treatment. Using a literature review approach， this study systematically summarizes the immune subtyping systems of sepsis and their molecular basis， and explores the potential correspondence between traditional Chinese medicine （TCM） syndromes and immune subtypes. It is found that the heat-toxin syndrome tends to correspond to the hyperinflammatory subtype， the stasis-toxin syndrome to the coagulopathy subtype， and the deficiency syndrome to the immunosuppressive subtype. These findings may provide new insights for precision therapy of sepsis through integrated Chinese and western medicine.

Background: s/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol can prevent hepatic decompensation in patients with high-risk CSPH stratified using the new model. Methods: Non-invasive risk factors of CSPH were identified via systematic review and meta-analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new non-invasive model was validated for various performance aspects in three cohorts, i.e., a multicenter HVPG cohort, a follow-up cohort, and a carvediloltreating cohort. Results: In the meta-analysis with six studies (n=819), liver stiffness measurement and platelet count were identified as independent risk factors for CSPH and were used to develop the new “CSPH risk” model. In the HVPG cohort (n=151), the new model accurately predicted CSPH with cutoff values of 0 and –0.68 for ruling in and out CSPH, respectively. In the follow-up cohort (n=1,102), the cumulative incidences of decompensation events significantly differed using the cutoff values of <–0.68 (low-risk), –0.68 to 0 (medium-risk), and >0 (high-risk). In the carvediloltreated cohort, patients with high-risk CSPH treated with carvedilol (n=81) had lower rates of decompensation events than non-selective beta-blockers untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=162 after PSM). Conclusions Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.

ObjectiveTo investigate the possible mechanism of Shenfuhuang Formula （参附黄配方） in prevention and treatment of epsis-associated encephalopathy from the perspective of brain genomics. MethodsC57BL/6 mice were randomly divided into sham surgery group， sepsis group， and Shenfuhuang group， with 20 mice in each group. The sepsis group and Shenfuhuang group were induced to develop sepsis by cecal ligation and puncture （CLP） procedure. At 4 hours after modelling， Shenfuhuang group were gavaged with 2.5 g/（kg·d） of Shenfuhuang Formula， 0.5 ml each time， at 12 hours intervals， for a total of 4 times after modelling. Sepsis group and sham surgery group were given 0.5 ml of purified water orally. At 48 hours after modeling， the transcriptome sequencing was used to explore the differential gene expression in the effects of Shenfuhuang Formula on the brain regions of septic mice， and real-time PCR and ELISA were later used to further validate the differential gene and proteins expression. ResultsA total of 4605 genes were differentially expressed in Shenfuhuang group compared with sepsis group， of which 2353 genes were up-regulated and 2252 genes were down-regulated. According to the results of previous publications， six key genes were screened， including serine/threonine-protein kinase （Nek1）， myelin-associated glycoprotein （Mag）， endothelial cell-specific tyrosine kinase receptor （Tek）， a disintegrin and metalloproteinase with thrombospondin motifs 20 （Adamts20）， lymphocyte antigen 86 （Ly86）， and E3 ubiquitin-protein ligase （Traip）. Further genetic and protein validation revealed that， compared to the sham surgery group， the mRNA levels and corresponding protein levels of Nek1， Mag， Tek， Adamts20， Ly86， and Traip in the brain tissue of septic mice significantly reduced （P＜0.05）. In comparison to the sepsis group， Shenfuhuang group showed significantly increased mRNA levels and corresponding protein levels of Nek1， Mag， Tek， Adamts20， Ly86， and Traip （P＜0.05）. ConclusionThe potential therapeutic targets of Shenfuhuang Formula for treating sepsis-associated encephalopathy may be related to the Nek1， Mag， Tek， Adamts20， Ly86， and Traip genes and their encoded proteins.

Objective To compare the efficacy and tolerability of the novel bowel-cleansing agent TCIC-001 and the traditional polyethylene glycol (PEG) regimen for bowel preparation prior to colonoscopy. Methods Prospective inclusion of 62 patients who were scheduled to undergo colonoscopy at Zhongshan Hospital, Fudan University from July 2021 to July 2022. They were randomly divided into TCIC-001 group (n=31) and PEG group (n=31) using a random number table method. The TCIC-001 group took TCIC-001 orally, drinking water in stages, with a total liquid intake of 1 500 mL; the PEG group took PEG orally, taking it in 4 doses, with a total liquid intake of 3 000 mL. The primary endpoint indicator is the quality of intestinal hygiene evaluated by the Boston Bowel Preparation Scale (BBPS), the secondary endpoint indicators were medication adherence, medication duration, frequency of bowel movements, duration of bowel movements, and incidence of adverse events between two groups. Results No significant differences were observed in sex, age, or defecation frequency between the two groups. For efficacy, both groups achieved equivalent bowel cleanliness, with a “good preparation” rate of 93.55% and comparable BBPS score of each intestinal segment and total scores. For tolerability, the TCIC-001 group had a shorter medication duration compared to the PEG group ([48.8±25.9] min vs [82.8±28.4] min, P<0.001), a longer defecation duration ([288.6±74.0] min vs [236.5±74.3] min, P<0.001), and a lower incidence of first defecation before medication completion (9.68% vs 41.94%, P=0.004). Regarding safety, no significant differences were observed between the TCIC-001 group and the PEG group in incidences of chloride disturbances (0% vs 9.68%) and calcium disturbances (3.23% vs 6.45%), and no other adverse events. Conclusions TCIC-001 demonstrated comparable bowel-cleansing efficacy to PEG while significantly improving tolerability (reduced medication time and lower risk of premature defecation) and maintaining favorable safety.

Given the escalating number of cancer patients and the consequent rise in demand for radiation therapy in China, there is an urgent need to establish and improve a talent cultivation system for radiation dosimetrists. The United States, with an early-established cultivation system for radiation dosimetrists, boasts relatively mature and comprehensive systems of academic education and qualification certification. This study summarized and analyzed the educational and certification patterns for radiation dosimetrists in the United States based on public data from relevant institutions, related literature, and interviews with American radiation dosimetrists. Meanwhile, this study delved into and assessed the shortcomings in China′s radiation dosimetry education, examination, certification, and career advancement pathways. Furthermore, this study offered suggestions and recommendations for constructing a novel pattern tailored to the cultivation of radiation dosimetrists in China, in order to facilitate the high-quality development of the medical dosimetry discipline.

Background: s/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol can prevent hepatic decompensation in patients with high-risk CSPH stratified using the new model. Methods: Non-invasive risk factors of CSPH were identified via systematic review and meta-analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new non-invasive model was validated for various performance aspects in three cohorts, i.e., a multicenter HVPG cohort, a follow-up cohort, and a carvediloltreating cohort. Results: In the meta-analysis with six studies (n=819), liver stiffness measurement and platelet count were identified as independent risk factors for CSPH and were used to develop the new “CSPH risk” model. In the HVPG cohort (n=151), the new model accurately predicted CSPH with cutoff values of 0 and –0.68 for ruling in and out CSPH, respectively. In the follow-up cohort (n=1,102), the cumulative incidences of decompensation events significantly differed using the cutoff values of <–0.68 (low-risk), –0.68 to 0 (medium-risk), and >0 (high-risk). In the carvediloltreated cohort, patients with high-risk CSPH treated with carvedilol (n=81) had lower rates of decompensation events than non-selective beta-blockers untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=162 after PSM). Conclusions Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.